XML 52 R38.htm IDEA: XBRL DOCUMENT v3.20.4
Non-controlling Interest (Details) - USD ($)
12 Months Ended
Sep. 05, 2018
Sep. 05, 2018
Aug. 31, 2015
Aug. 29, 2015
Dec. 31, 2020
Dec. 31, 2019
Noncontrolling Interest            
Equity Method Investment, Ownership Percentage         83.00%  
Related Party Transaction, Expenses from Transactions with Related Party $ 328,000          
Research and Development Expense   $ 198,000     $ 5,131,000 $ 11,083,000
Fair Value Of Shares Issued   $ 285,000        
Net Income (Loss) Attributable to Noncontrolling Interest         (73,000) (77,000)
Stock Purchase Agreement [Member]            
Noncontrolling Interest            
Conversion of Stock, Shares Issued     38,572      
Research and Development Expense $ 225,000       $ 225,000 198,000
Conversion of Stock, Shares Converted       38,572    
SYN Biomics [Member]            
Noncontrolling Interest            
Equity Method Investment, Ownership Percentage 88.50% 88.50%     83.00%  
Equity interest by parent 11.50% 11.50%   8.50% 17.00%  
Additional Number Of Common Stock To Be Issued 2,420,000 2,420,000        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners         17.00%  
Net Income (Loss) Attributable to Noncontrolling Interest         $ 2,800,000 2,900,000
Dr. Pimentels [Member]            
Noncontrolling Interest            
Net Income (Loss) Attributable to Noncontrolling Interest           77,000,000,000
Dr. Pimentels [Member] | Consolidation, Eliminations            
Noncontrolling Interest            
Net Income (Loss) Attributable to Noncontrolling Interest           $ 505,000
Cedarssinai Medical Center [Member]            
Noncontrolling Interest            
Number Of Common Stock To Be Issued 50,000 50,000        
Number Of Common Stock To Be Held By Related Party 7,480,000 7,480,000        
Cedarssinai Medical Center [Member] | SYN Biomics [Member]            
Noncontrolling Interest            
Additional Number Of Common Stock To Be Issued 2,420,000 2,420,000